Update 9.22 AM EST: Adds comments from Illumina The EU regulators on Friday approved plans by U.S. genomics company Illumina (NASDAQ:ILMN) to divest Grail, the cancer test developer it acquired in ...

What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many shareholders. This may have investors wondering how to approach the situation.

That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

China's "blacklist of entities" now has two more entries -- Illumina and fashion conglomerate PVH-- after its government put the companies on notice late Monday. The move is clearly a retaliatory ...

11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor ...

Throughout the last three months, 7 analysts have evaluated Illumina (NASDAQ:ILMN), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of ...

China’s Ministry of Commerce said it would ban Illumina, a San Diego company, from importing its gene-mapping products in China. Illumina is the world’s leading producer of gene-sequencing ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.